Xanadu Bio Raises $11M to Advance PACE Nanoparticle Technology

Xanadu Bio, a privately held, next-generation nanoparticle delivery company, has secured $11 million in investment capital from investors. This funding round marks a significant milestone for the biotechnology firm as it advances its innovative PACE platform technology for the delivery of mRNA and other nucleic acids. The company's proprietary PACE technology is a next-generation polymeric nanoparticle system designed for the efficient and safe delivery of various nucleic acids, including mRNA. Composed of three fully biodegradable monomers, PACE offers robust protection from nuclease degradation. Its design facilitates easy manufacturing, cost-effective production, and scalability, with the added capability of being functionalized for organ and cell-specific delivery of its nucleic acid payload. PACE is formulated to enable safe administration both systemically and intranasally, positioning Xanadu Bio at the forefront of advanced delivery solutions. The $11 million in new funding will be instrumental in accelerating the development of Xanadu Bio’s PACE platform and expanding its pipeline initiatives. Leveraging its versatile technology, Xanadu Bio is initially focused on developing nasal vaccine boosters, particularly for the prevention and treatment of SARS CoV-2 infection, with plans to extend applications to other indications. This capital injection underscores investor confidence in the company's technology and its potential to address critical unmet needs in drug delivery. Xanadu Bio plans to use the funds for growth initiatives, including further research and development of its nanoparticle delivery systems and the progression of its therapeutic programs. This investment is expected to bolster the company's efforts to bring its advanced delivery solutions to market, ultimately aiming to enhance therapeutic efficacy and patient outcomes across a range of diseases.